ClinicalTrials.gg
TerminatedNCT05613088Updated Oct 28, 2026Results posted

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Phase 2 interventional study of MORAb-202 and Paclitaxel in Neoplasms, Ovarian, sponsored by Bristol-Myers Squibb. Terminated at 50 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
Business objectives have changed.
Updated Oct 28, 2026Now TerminatedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies testing paclitaxel in Ovarian Neoplasms — 13 open to participants now, 21 under way, 6 of them phase 3. Paclitaxel · Ovarian Neoplasms.

Enrollment
39th of 143
106 · median 50
Started
2023
with 4 others
Phase 2
83 of 155
8 open now
Registered
147th of 155
by date

Among the 155 studies testing paclitaxel in Ovarian Neoplasms, this one is the 39th largest by enrollment of the 143 interventional ones that give a count, is one of 5 that started in 2023, is one of 83 in phase 2, and was the 147th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 155 studies testing paclitaxel in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing paclitaxel in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.

03

Conditions studied

  • Neoplasms, Ovarian

Keywords

  • Platinum-resistant ovarian cancer (PROC)
  • Primary peritoneal cancer
  • Fallopian tube cancer
  • MORAb-202
  • Folate-receptor alpha
  • ADC
  • Antibody-drug conjugate
  • Epithelial ovarian cancer
  • High grade serous
  • Farletuzumab ecteribulin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants with -confirmed diagnosis of HGS ovarian, primary peritoneal, or fallopian tube cancer.
  • Platinum-resistant disease, defined as:
  • For participants who had only 1 line of platinum-based therapy: progression between > 1 month and ≤ 6 months after the last dose of platinum-based therapy of at least 4 cycles.
  • For participants who had 2 or 3 lines of platinum-based therapy: progression ≤ 6 months after the last dose of platinum-based therapy.
  • Participants have received at least 1 but no more than 3 and for whom single-agent therapy is appropriate as the next line of therapy. Participants may have been treated with up to 1 line of therapy subsequent to determination of platinum-resistance.
  • Disease progression per v1.1 (by investigator assessment) of at least 1 on or after the most recent therapy.
  • Either formalin-fixed, paraffin-embedded (FFPE) tissue (up to 5 years old) or newly-obtained must be available for FRα assessment prior to randomization.
  • Performance Status (ECOG PS) of 0 or 1.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  • Clear cell, mucinous, endometrioid or sarcomatous histology, or mixed tumors containing components of any of these histologies, or low grade or borderline ovarian cancer.
  • Primary platinum- ovarian cancer defined as disease progression within 1 month of the last dose of the platinum-containing regimen.
  • Pulmonary function test (PFT) abnormalities: \< 70% or FVC \< 60%, and DLCO \< 80%.
  • Investigator-assessed current ILD/pneumonitis, or ILD/pneumonitis suspected at screening or history of ILD/pneumonitis of any severity including ILD/pneumonitis from prior anti-cancer therapy.
  • Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage.

Physical and Laboratory Test Findings

  • Evidence of organ dysfunction or any clinically-significant deviation from normal in physical examination, vital signs, , or clinical laboratory determinations beyond what is consistent with the target population.

Allergies and Adverse Drug Reactions

  • Has any prior severe (≥ Grade 3) to monoclonal antibodies or eribulin or to the receipt of or any of the (investigators should refer to the prescribing information for the selected corticosteroid).
  • History of allergy or contraindication to IC chemotherapy agent selected if randomized to Arm C.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    MORAb-202

    Drug: MORAb-202

  • Experimental
    Investigator's Choice Chemotherapy

    Drug: Paclitaxel · Drug: Pegylated Liposomal Doxorubicin (PLD) · Drug: Topotecan

Interventions

  • Specified dose on specified days

    Also known as: BMS-986445, Farletuzumab Ecteribulin

  • Specified dose on specified days

    Also known as: Bendalis

  • Specified dose on specified days

    Also known as: Caelyx

  • Specified dose on specified days

    Also known as: Hycamtin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment

    Objective Response Rate (ORR) is defined as the number of randomized participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on investigator assessments \[using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\], divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of randomization to the date of first objectively-documented progression or the date of subsequent therapy (Up to approximately 70 weeks)

  2. Number of Participants With Treatment-Related Adverse Event (TRAEs) Leading to Discontinuation Within 6 Months From First Dose

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.

    Time frame: From first dose of study medication up to 6 months

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.

    Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)

  2. Number of Participants With Serious Adverse Events (SAEs)

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)

  3. Number of Participants With AEs Leading to Discontinuation

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.

    Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)

  4. Number of Participants With Treatment-Related AEs

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.

    Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)

  5. Number of Participants With Treatment-Related SAEs

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)

  6. Number of Participants With AEs of Special Interest (AESIs)

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention. An adverse event of special interest (AESI) is an AE (serious or nonserious) of scientific and medical concern specific to the sponsor's product/program that may require further investigation. AESIs for MORAb-202 include infusion-related reactions and interstitial lung disease (ILD)/pneumonitis. The number of participants experiencing at least one AESI was assessed during the study.

    Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)

  7. Number of Participants Who Died

    Number of participants who died during the study.

    Time frame: From first dose of study medication until death due to any cause (up to 136 weeks)

  8. Number of Participants With Grade 3-4 Laboratory Abnormalities

    Number of participants experiencing most frequently reported clinical abnormalities in laboratory testing including hematology, chemistry, liver function, and renal function. Laboratory findings are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)

  9. Disease Control Rate (DCR) by RECIST v1.1 Per Investigator Assessment

    Disease Control Rate (DCR) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on investigator assessments (using RECIST v1.1) divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Clopper and Pearson estimates of duration of response

    Time frame: From randomization until disease progression, withdrawal from study treatment, initiation of new therapy, or study completion, whichever occurred first (up to approximately 136 weeks)

  10. Duration of Response (DoR) by RECIST v1.1 Per Investigator Assessment

    Duration of Response (DoR) is defined as the time between the date of first documented response (CR or PR) confirmed, to the date of the first objectively documented tumor progression by investigator (per RECIST v1.1) or death, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Kaplan-Meier estimates of duration of response

    Time frame: From first documented response (complete response or partial response) until first documented disease progression or death, whichever occurred first (up to approximately 136 weeks)

  11. Progression-free Survival (PFS) by RECIST v1.1 Per Investigator Assessment

    Progression-free Survival (PFS) is defined as the time between the date of randomization and the first date of documented progression, per investigator assessments (using RECIST v1.1), or death due to any cause, whichever occurs first. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Kaplan-Meier estimates of progression-free survival

    Time frame: From the date of randomization to the first date of documented progression, or death whichever occurs first (Up to approximately 136 weeks)

07

Results

Posted Jul 3, 2025

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestoneMORAb-202Investigator's Choice (IC) Chemotherapy
Started7036
Completed7034
Not completed02
Treatment
Participant flow — Treatment
MilestoneMORAb-202Investigator's Choice (IC) Chemotherapy
Started7034
Completed20
Not completed6834
Withdrew: Study terminated by sponsor01
Withdrew: Adverse event32
Withdrew: Other reasons12
Withdrew: Progressive disease6425
Withdrew: Withdrawal by subject04

Outcome measures

PrimaryObjective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment

Objective Response Rate (ORR) is defined as the number of randomized participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on investigator assessments \[using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\], divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of randomization to the date of first objectively-documented progression or the date of subsequent therapy (Up to approximately 70 weeks)
Reported as:
Number · Percent of participants
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment
Percent of participantsMORAb-202Investigator's Choice (IC) Chemotherapy
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment20.0 (11.4 to 31.3)13.9 (4.7 to 29.5)
PrimaryNumber of Participants With Treatment-Related Adverse Event (TRAEs) Leading to Discontinuation Within 6 Months From First Dose

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.

Time frame:
From first dose of study medication up to 6 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Adverse Event (TRAEs) Leading to Discontinuation Within 6 Months From First Dose
ParticipantsMORAb-202Investigator's Choice (IC) Chemotherapy
Number of Participants With Treatment-Related Adverse Event (TRAEs) Leading to Discontinuation Within 6 Months From First Dose20
SecondaryNumber of Participants With Adverse Events (AEs)

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.

Time frame:
From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsMORAb-202Investigator's Choice (IC) Chemotherapy
Number of Participants With Adverse Events (AEs)6732
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsMORAb-202Investigator's Choice (IC) Chemotherapy
Number of Participants With Serious Adverse Events (SAEs)1911
SecondaryNumber of Participants With AEs Leading to Discontinuation

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.

Time frame:
From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Discontinuation
ParticipantsMORAb-202Investigator's Choice (IC) Chemotherapy
Number of Participants With AEs Leading to Discontinuation41
SecondaryNumber of Participants With Treatment-Related AEs

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.

Time frame:
From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related AEs
ParticipantsMORAb-202Investigator's Choice (IC) Chemotherapy
Number of Participants With Treatment-Related AEs5329
SecondaryNumber of Participants With Treatment-Related SAEs

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related SAEs
ParticipantsMORAb-202Investigator's Choice (IC) Chemotherapy
Number of Participants With Treatment-Related SAEs12
SecondaryNumber of Participants With AEs of Special Interest (AESIs)

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention. An adverse event of special interest (AESI) is an AE (serious or nonserious) of scientific and medical concern specific to the sponsor's product/program that may require further investigation. AESIs for MORAb-202 include infusion-related reactions and interstitial lung disease (ILD)/pneumonitis. The number of participants experiencing at least one AESI was assessed during the study.

Time frame:
From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With AEs of Special Interest (AESIs)
ParticipantsMORAb-202Investigator's Choice (IC) Chemotherapy
Infusion-related reactions11
Interstitial lung disease (ILD)30
Pneumonitis130
SecondaryNumber of Participants Who Died

Number of participants who died during the study.

Time frame:
From first dose of study medication until death due to any cause (up to 136 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsMORAb-202Investigator's Choice (IC) Chemotherapy
Number of Participants Who Died3620
SecondaryNumber of Participants With Grade 3-4 Laboratory Abnormalities

Number of participants experiencing most frequently reported clinical abnormalities in laboratory testing including hematology, chemistry, liver function, and renal function. Laboratory findings are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3-4 Laboratory Abnormalities
ParticipantsMORAb-202Investigator's Choice (IC) Chemotherapy
Grade 3: Absolute Lymphocytes Decreased40
Grade 3: Absolute Neutrophil Decreased39
SecondaryDisease Control Rate (DCR) by RECIST v1.1 Per Investigator Assessment

Disease Control Rate (DCR) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on investigator assessments (using RECIST v1.1) divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Clopper and Pearson estimates of duration of response

Time frame:
From randomization until disease progression, withdrawal from study treatment, initiation of new therapy, or study completion, whichever occurred first (up to approximately 136 weeks)
Reported as:
Number · Percent of participants
Disease Control Rate (DCR) by RECIST v1.1 Per Investigator Assessment
Percent of participantsMORAb-202Investigator's Choice (IC) Chemotherapy
Disease Control Rate (DCR) by RECIST v1.1 Per Investigator Assessment80.0 (68.7 to 88.6)69.4 (51.9 to 83.7)
SecondaryDuration of Response (DoR) by RECIST v1.1 Per Investigator Assessment

Duration of Response (DoR) is defined as the time between the date of first documented response (CR or PR) confirmed, to the date of the first objectively documented tumor progression by investigator (per RECIST v1.1) or death, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Kaplan-Meier estimates of duration of response

Time frame:
From first documented response (complete response or partial response) until first documented disease progression or death, whichever occurred first (up to approximately 136 weeks)
Reported as:
Median · Months
Duration of Response (DoR) by RECIST v1.1 Per Investigator Assessment
MonthsMORAb-202Investigator's Choice (IC) Chemotherapy
Duration of Response (DoR) by RECIST v1.1 Per Investigator Assessment4.44 (2.79 to 7.13)7.62 (2.37 to NA)
SecondaryProgression-free Survival (PFS) by RECIST v1.1 Per Investigator Assessment

Progression-free Survival (PFS) is defined as the time between the date of randomization and the first date of documented progression, per investigator assessments (using RECIST v1.1), or death due to any cause, whichever occurs first. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Kaplan-Meier estimates of progression-free survival

Time frame:
From the date of randomization to the first date of documented progression, or death whichever occurs first (Up to approximately 136 weeks)
Reported as:
Median · Months
Progression-free Survival (PFS) by RECIST v1.1 Per Investigator Assessment
MonthsMORAb-202Investigator's Choice (IC) Chemotherapy
Progression-free Survival (PFS) by RECIST v1.1 Per Investigator Assessment4.01 (2.79 to 4.67)4.30 (3.71 to 5.55)
Statistical analysis
  • MORAb-202 vs Investigator's Choice (IC) Chemotherapy · Log Rank · p = 0.3359 · Hazard ratio (hr): 1.25 · 95% CI 0.79 to 1.96
Post-hocObjective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment

Objective Response Rate (ORR) is defined as the number of randomized participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on investigator assessments \[using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\], divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of randomization to the date of first objectively-documented progression or the date of subsequent therapy (Up to approximately 136 weeks)
Reported as:
Number · Percent of participants
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment
Percent of participantsMORAb-202Investigator's Choice (IC) Chemotherapy
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment21.4 (12.5 to 32.9)16.7 (6.4 to 32.8)

Adverse events

Collected over Participants were assessed for all-cause mortality from randomization until death or study completion (up to approximately 136 weeks). Serious Adverse Events (SAEs) and Other Adverse Events (AEs) from first dose of study medication through 100 days after the last dose of study treatment (up to approximately 119 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MORAb-20236/70 (51.4%)22/70 (31.4%)61/70 (87.1%)
Investigator's Choice (IC) Chemotherapy20/36 (55.6%)11/34 (32.4%)31/34 (91.2%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventMORAb-202Investigator's Choice (IC) Chemotherapy
Intestinal obstructionGastrointestinal disorders5/703/34
Intestinal pseudo-obstructionGastrointestinal disorders1/702/34
PyrexiaGeneral disorders1/702/34
Abdominal painGastrointestinal disorders3/700/34
Small intestinal obstructionGastrointestinal disorders3/700/34
AscitesGastrointestinal disorders0/701/34
Duodenal obstructionGastrointestinal disorders1/701/34
IleusGastrointestinal disorders2/701/34
Rectal haemorrhageGastrointestinal disorders0/701/34
Head injuryInjury, poisoning and procedural complications0/701/34
Most frequent other events
Showing 10 of 56
Most frequent other events
EventMORAb-202Investigator's Choice (IC) Chemotherapy
NauseaGastrointestinal disorders17/7015/34
NeutropeniaBlood and lymphatic system disorders7/7011/34
ConstipationGastrointestinal disorders17/709/34
Neutrophil count decreasedInvestigations2/709/34
AnaemiaBlood and lymphatic system disorders10/708/34
Abdominal painGastrointestinal disorders15/703/34
StomatitisGastrointestinal disorders0/707/34
FatigueGeneral disorders11/707/34
HeadacheNervous system disorders14/701/34
PneumonitisRespiratory, thoracic and mediastinal disorders13/700/34

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MORAb-202Investigator's Choice (IC) ChemotherapyTotal
Mean58.3 ± 9.1561.3 ± 12.1659.3 ± 10.31
Sex: Female, Male
Sex: Female, Male(Participants)MORAb-202Investigator's Choice (IC) ChemotherapyTotal
Female7036106
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MORAb-202Investigator's Choice (IC) ChemotherapyTotal
Hispanic or Latino12719
Not Hispanic or Latino572986
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MORAb-202Investigator's Choice (IC) ChemotherapyTotal
American Indian or Alaska Native000
Asian171128
Native Hawaiian or Other Pacific Islander000
Black or African American112
White502474
More than one race000
Unknown or Not Reported202
08

Study locations

50 sites
  • Local Institution - 0065
    Sacramento, California 95817, United States
  • Local Institution - 0025
    San Francisco, California 94109, United States
  • Local Institution - 0078
    Whittier, California 90602-3171, United States
  • Local Institution - 0081
    South Bend, Indiana 46601-1033, United States
  • Local Institution - 0043
    Kansas City, Kansas 66160, United States
  • Local Institution - 0023
    Canton, Ohio 44710-1702, United States
  • Local Institution - 0061
    Columbus, Ohio 43219, United States
  • Local Institution - 0044
    Nashville, Tennessee 37203-1625, United States
  • Local Institution - 0082
    Salt Lake City, Utah 84124, United States
  • Local Institution - 0042
    Spokane, Washington 99204, United States
  • Local Institution - 0016
    Sydney, New South Wales 2065, Australia
  • Local Institution - 0017
    Waratah, New South Wales 2298, Australia
  • Local Institution - 0031
    Chermside, Queensland 4032, Australia
  • Local Institution - 0015
    Clayton, Victoria 3168, Australia
  • Local Institution - 0027
    Malvern, Victoria 3144, Australia
  • Local Institution - 0058
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0032
    Leuven, VBR 3000, Belgium
  • Local Institution - 0013
    Namur, WNA 5000, Belgium
  • Local Institution - 0012
    Brussels, 1200, Belgium
  • Local Institution - 0045
    Liège, 4000, Belgium
  • Local Institution - 0030
    Santiago, RM 8420323, Chile
  • Local Institution - 0036
    Santiago, 7510032, Chile
  • Local Institution - 0029
    Temuco, 4800827, Chile
  • Local Institution - 0046
    Jerusaelm, JM 9112001, Israel
  • Local Institution - 0054
    Haifa, 31999, Israel
  • Local Institution - 0080
    Jerusalem, 91031, Israel
  • Local Institution - 0055
    Ramat Gan, 5265601, Israel
  • Local Institution - 0048
    Tel Aviv, 64239, Israel
  • Local Institution - 0003
    Bologna, BO 40138, Italy
  • Local Institution - 0011
    Milan, MI 20132, Italy
  • Local Institution - 0009
    Milan, MI 20141, Italy
  • Local Institution - 0010
    Roma, RM 00168, Italy
  • Local Institution - 0002
    Brescia, 25123, Italy
  • Local Institution - 0018
    Akashi, Hyogo, 673-8558, Japan
  • Local Institution - 0019
    Chūōku, 104-0045, Japan
  • Local Institution - 0014
    Hidaka-shi, 350-1298, Japan
  • Local Institution - 0004
    Kurume-Shi, 830-0011, Japan
  • Local Institution - 0037
    Tokyo, 135-8550, Japan
  • Local Institution - 0056
    Seoul, 03080, South Korea
  • Local Institution - 0049
    Seoul, 03722, South Korea
  • Local Institution - 0053
    Seoul, 5505, South Korea
  • Local Institution - 0039
    Barcelona, B 08035, Spain
  • Local Institution - 0005
    Madrid, M 28007, Spain
  • Local Institution - 0001
    Madrid, M 28041, Spain
  • Local Institution - 0007
    Valencia, V 46009, Spain
  • Local Institution - 0006
    Valencia, V 46010, Spain
  • Local Institution - 0021
    Barcelona, 08036, Spain
  • Local Institution - 0020
    Girona, 17007, Spain
  • Local Institution - 0038
    Madrid, 28033, Spain
  • Local Institution - 0022
    Madrid, 28046, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Jun 2024, 16 months.

Results were first posted in Jul 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2022
First posted
Nov 14, 2022
StartActual
Feb 1, 2023
Primary completionActual
Jun 17, 2024
CompletionActual
Sep 10, 2025
Results first posted
Jul 3, 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated Business objectives have changed.
changed Oct 28, 2026
Results
Posted results revised
revised Oct 28, 2026
Documents
Secondary outcomes
11 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameNumber of Participants With Adverse Events (AEs)From the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
  • Time frameNumber of Participants With Serious Adverse Events (SAEs)From the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
  • Time frameNumber of Participants With AEs Leading to DiscontinuationFrom the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
  • Time frameNumber of Participants With Treatment-Related AEsFrom the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
  • Time frameNumber of Participants With Treatment-Related SAEsFrom the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
  • Time frameNumber of Participants With AEs of Special Interest (AESIs)From the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
  • Time frameNumber of Participants Who DiedFrom first dose of study medication until death due to any cause (up to 70 weeks) → From first dose of study medication until death due to any cause (up to 136 weeks)
  • Time frameNumber of Participants With Grade 3-4 Laboratory AbnormalitiesFrom the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
  • Time frameDisease Control Rate (DCR) by RECIST v1.1 Per Investigator AssessmentFrom the date of randomization to the first date of documented progression, or death whichever occurs first (Up to approximately 70 weeks) → From randomization until disease progression, withdrawal from study treatment, initiation of new therapy, or study completion, whichever occurred first (up to approximately 136 weeks)
  • Time frameDuration of Response (DoR) by RECIST v1.1 Per Investigator AssessmentFrom the date of first dose to the date of the first documented tumor progression, or death, whichever occurs first (Up to approximately 70 weeks) → From first documented response (complete response or partial response) until first documented disease progression or death, whichever occurred first (up to approximately 136 weeks)
  • Time frameProgression-free Survival (PFS) by RECIST v1.1 Per Investigator AssessmentFrom the date of randomization to the first date of documented progression, or death whichever occurs first (Up to approximately 70 weeks) → From the date of randomization to the first date of documented progression, or death whichever occurs first (Up to approximately 136 weeks)
  • DescriptionNumber of Participants With AEs of Special Interest (AESIs): how it is measured was reworded
  • DescriptionNumber of Participants With Grade 3-4 Laboratory Abnormalities: how it is measured was reworded
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Completed→Terminated
    Why stopped Business objectives have changed.
    Posted results revised
    Secondary outcomes 11 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameNumber of Participants With Adverse Events (AEs)From the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
    • Time frameNumber of Participants With Serious Adverse Events (SAEs)From the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
    • Time frameNumber of Participants With AEs Leading to DiscontinuationFrom the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
    • Time frameNumber of Participants With Treatment-Related AEsFrom the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
    • Time frameNumber of Participants With Treatment-Related SAEsFrom the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
    • Time frameNumber of Participants With AEs of Special Interest (AESIs)From the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
    • Time frameNumber of Participants Who DiedFrom first dose of study medication until death due to any cause (up to 70 weeks) → From first dose of study medication until death due to any cause (up to 136 weeks)
    • Time frameNumber of Participants With Grade 3-4 Laboratory AbnormalitiesFrom the first dose of study medication until 17Jun2024, which is 30 days after the last dose of study treatment (assessed for an average duration of approximately 5 months, with a maximum of up to 14 months) → From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
    • Time frameDisease Control Rate (DCR) by RECIST v1.1 Per Investigator AssessmentFrom the date of randomization to the first date of documented progression, or death whichever occurs first (Up to approximately 70 weeks) → From randomization until disease progression, withdrawal from study treatment, initiation of new therapy, or study completion, whichever occurred first (up to approximately 136 weeks)
    • Time frameDuration of Response (DoR) by RECIST v1.1 Per Investigator AssessmentFrom the date of first dose to the date of the first documented tumor progression, or death, whichever occurs first (Up to approximately 70 weeks) → From first documented response (complete response or partial response) until first documented disease progression or death, whichever occurred first (up to approximately 136 weeks)
    • Time frameProgression-free Survival (PFS) by RECIST v1.1 Per Investigator AssessmentFrom the date of randomization to the first date of documented progression, or death whichever occurs first (Up to approximately 70 weeks) → From the date of randomization to the first date of documented progression, or death whichever occurs first (Up to approximately 136 weeks)
    • DescriptionNumber of Participants With AEs of Special Interest (AESIs): how it is measured was reworded
    • DescriptionNumber of Participants With Grade 3-4 Laboratory Abnormalities: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05613088
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Feb 1, 2023
Primary completion
Jun 17, 2024
Completion
Sep 10, 2025
Results posted
Jul 3, 2025
Last update
Oct 28, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MORAb-202 · Paclitaxel · Liposomal doxorubicin · Topotecan

Start the discussion